Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1992 Dec;66(6):1088–1093. doi: 10.1038/bjc.1992.415

A model of multiple myeloma: culture of 5T33 murine myeloma cells and evaluation of tumorigenicity in the C57BL/KaLwRij mouse.

L S Manning 1, J D Berger 1, H L O'Donoghue 1, G N Sheridan 1, P G Claringbold 1, J H Turner 1
PMCID: PMC1978028  PMID: 1457349

Abstract

The 5T33 multiple myeloma is one of a series of transplantable murine myelomas arising spontaneously in C57BL/KaLwRij mice. This study describes the establishment and characterisation of the 5T33 murine myeloma in vitro as a cultured cell line in terms of its morphology, growth rate, expression of paraprotein (IgG2b) and tumorigenicity in syngeneic animals. The 5T33 cell line has been in continuous culture for over 10 months and has achieved more than passage 34. In culture, 5T33 myeloma grows as single cells or in small clusters of loosely adherent cells on an adherent stromal cell layer. Maximum doubling time is approximately 25 h, and over 90% of the cells express cytoplasmic IgG2b paraprotein. The cultured 5T33 myeloma cells are highly tumorigenic in C57BL/KaLwRij mice with as few as 500 cells inducing paralysis and death as early as day 36 post-tumour inoculation. Kinetics of tumour development and detection of IgG2b paraprotein are dose dependent. Two weeks following intravenous inoculation of 5 x 10(5) cultured 5T33 myeloma cells, tumour cells were readily identified in the bone marrow. By 3 weeks post-tumour inoculation, 5T33 myeloma cells were found in various tissues throughout the animal. Studies are now underway to determine the sensitivity of this cell line to various therapeutic modalities.

Full text

PDF
1088

Images in this article

1090Figure 1
on p.1090

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Alexanian R., Dreicer R. Chemotherapy for multiple myeloma. Cancer. 1984 Feb 1;53(3):583–588. doi: 10.1002/1097-0142(19840201)53:3<583::aid-cncr2820530336>3.0.co;2-1. [DOI] [PubMed] [Google Scholar]
  2. Barlogie B., Alexanian R., Dicke K. A., Zagars G., Spitzer G., Jagannath S., Horwitz L. High-dose chemoradiotherapy and autologous bone marrow transplantation for resistant multiple myeloma. Blood. 1987 Sep;70(3):869–872. [PubMed] [Google Scholar]
  3. Barlogie B., Epstein J., Selvanayagam P., Alexanian R. Plasma cell myeloma--new biological insights and advances in therapy. Blood. 1989 Mar;73(4):865–879. [PubMed] [Google Scholar]
  4. Barlogie B. Toward a cure for multiple myeloma? N Engl J Med. 1991 Oct 31;325(18):1304–1306. doi: 10.1056/NEJM199110313251809. [DOI] [PubMed] [Google Scholar]
  5. Croese J. W., Van den Enden-Vieveen M. H., Radl J. Immune regulation of 5T2 mouse multiple myeloma. II. Immunological treatment of 5T2 MM residual disease. Neoplasma. 1991;38(5):467–474. [PubMed] [Google Scholar]
  6. Croese J. W., Vas Nunes C. M., Radl J., van den Enden-Vieveen M. H., Brondijk R. J., Boersma W. J. The 5T2 mouse multiple myeloma model: characterization of 5T2 cells within the bone marrow. Br J Cancer. 1987 Nov;56(5):555–560. doi: 10.1038/bjc.1987.241. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Croese J. W., Vissinga C. S., Boersma W. J., Radl J. Immune regulation of mouse 5T2 multiple myeloma. I. Immune response to 5T2 MM idiotype. Neoplasma. 1991;38(5):457–466. [PubMed] [Google Scholar]
  8. Hjorth M., Hellquist L., Holmberg E., Magnusson B., Rödjer S., Westin J. Initial treatment in multiple myeloma: no advantage of multidrug chemotherapy over melphalan-prednisone. The Myeloma Group of Western Sweden. Br J Haematol. 1990 Feb;74(2):185–191. doi: 10.1111/j.1365-2141.1990.tb02564.x. [DOI] [PubMed] [Google Scholar]
  9. Jeppsson J. O., Laurell C. B., Franzén B. Agarose gel electrophoresis. Clin Chem. 1979 Apr;25(4):629–638. [PubMed] [Google Scholar]
  10. Kyle R. A., Greipp P. R., Gertz M. A. Treatment of refractory multiple myeloma and considerations for future therapy. Semin Oncol. 1986 Sep;13(3):326–333. [PubMed] [Google Scholar]
  11. McElwain T. J., Powles R. L. High-dose intravenous melphalan for plasma-cell leukaemia and myeloma. Lancet. 1983 Oct 8;2(8354):822–824. doi: 10.1016/s0140-6736(83)90739-0. [DOI] [PubMed] [Google Scholar]
  12. Mellstedt H., Holm G., Björkholm M. Multiple myeloma, Waldenström's macroglobulinemia, and benign monoclonal gammopathy: characteristics of the B cell clone, immunoregulatory cell populations and clinical implications. Adv Cancer Res. 1984;41:257–289. doi: 10.1016/s0065-230x(08)60018-4. [DOI] [PubMed] [Google Scholar]
  13. Radl J., Croese J. W., Zurcher C., Van den Enden-Vieveen M. H., de Leeuw A. M. Animal model of human disease. Multiple myeloma. Am J Pathol. 1988 Sep;132(3):593–597. [PMC free article] [PubMed] [Google Scholar]
  14. Radl J., Croese J. W., Zurcher C., van den Enden-Vieveen M. H., Brondijk R. J., Kazil M., Haaijman J. J., Reitsma P. H., Bijvoet O. L. Influence of treatment with APD-bisphosphonate on the bone lesions in the mouse 5T2 multiple myeloma. Cancer. 1985 Mar 1;55(5):1030–1040. doi: 10.1002/1097-0142(19850301)55:5<1030::aid-cncr2820550518>3.0.co;2-y. [DOI] [PubMed] [Google Scholar]
  15. Von Hoff D. D. He's not going to talk about in vitro predictive assays again, is he? J Natl Cancer Inst. 1990 Jan 17;82(2):96–101. doi: 10.1093/jnci/82.2.96. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES